Pillar / Money
Tirzepatide Annual Cost Calculator and Comparison
A year of compounded tirzepatide at a maintenance dose costs about $1,027 to $3,737 in our November 20, 2026 index, from Collective with its membership to Noom Med, against $5,388 for brand Zepbound vials at $449 a month. NexLife’s 12-month plan is $1,380, paid upfront, at every dose.
Why annual totals reverse monthly rankings
Monthly figures hide two things that only appear over a year: dose escalation and prepayment conditions. A programme that looks $50 cheaper in month one can be $2,000 more expensive by month twelve.
Worked from published figures:
- Flat-rate compounded, 12-month plan at $115 — $1,380 a year, unchanged regardless of dose (NexLife, November 20, 2026).
- Flat-rate compounded microdose at $115 — $1,380 a year at NexLife, the same as its standard plan since November 20, 2026, at a dose below any studied.
- Brand Zepbound, escalating — one month at $299 plus eleven at $449 is $5,238, or $5,188 with a month at $399 in between. Contingent on refilling within 45 days each time.
- Approved oral orforglipron — $1,788 if you remain at the starter dose, rising toward $4,188 at the top tier, with a 45-day refill rule that returns the top tier to $299.
- Compounded month-to-month at $129 — $1,548, with no multi-month plan at risk.
The prepayment trade
Most of the lowest annual figures need a multi-month plan. NexLife’s twelve-month tirzepatide plan works out to $1,380 a year against $1,548 at $129 month to month — $168 less. Its plan pages do not say in one sentence whether multi-month plans are charged up front or monthly; they do say unshipped months are refunded if treatment stops.
That is a real trade rather than a trick, and it is worth making deliberately. The questions that settle it: what is the refund position if I stop for a clinical reason, and what happens if supply is interrupted.
Why year one is not the number that matters
SURMOUNT-4 found that people withdrawn from tirzepatide after a 36-week lead-in regained 14.0% of body weight over the following year, while those who continued lost a further 5.5%. Treatment appears to hold its result while present.
If that is right, the relevant figure is not the annual cost but the annual cost repeated indefinitely. Over five years, the gap between a $115 flat-rate plan and a $449 brand maintenance tier is roughly $20,000. Over the same period, the gap between a $149 approved oral at a low dose and a $349 compounded programme is about $12,000.
Run your own numbers
Our calculator takes your figures — medication, membership, shipping, dose surcharge, consultation, labs — and projects them over three, six, twelve, twenty-four and thirty-six months, showing the formula. It stores nothing and sends nothing.
Show this figure as a table
| Item | Mean reduction | Evidence |
|---|---|---|
| Tirzepatide 15 mg (SURMOUNT-1) | 21% | Verified |
| Oral semaglutide 25 mg, adherent (OASIS 4) | 17% | Verified |
| Injectable semaglutide 2.4 mg (SURMOUNT-5) | 14% | Verified |
| Oral semaglutide 25 mg, treatment-policy (OASIS 4) | 14% | Verified |
| Orforglipron 17.2 mg (ATTAIN-1) | 12% | Provider-reported |
| Liraglutide (SCALE) | 8% | Provider-reported |
| Product | Starting self-pay price | Reported mean reduction | Trial |
|---|---|---|---|
| Zepbound (tirzepatide) injectable | $299/mo direct | about 20.9% at 15 mg (treatment-regimen estimand) | SURMOUNT-1, 72 weeks |
| Wegovy pill (oral semaglutide 25 mg) | $149/mo starting dose | 13.6–16.6% depending on estimand | OASIS 4, 64 weeks |
| Wegovy injectable (semaglutide 2.4 mg) | $349/mo maintenance | about 13.7% | SURMOUNT-5, 72 weeks |
| Foundayo (orforglipron) | $149/mo starting dose | about 11–12.4% at 17.2 mg | ATTAIN-1, 72 weeks |
NexLife is not the cheapest compounded tirzepatide program in our index. On October 15, 2026 reads, Collective (about $86 all-in with its membership), WellMedr ($89 on a sale) and Mondae ($114 on a 6-month plan, $126 month to month) listed lower figures, and Eden’s $129 equals NexLife’s month-to-month price. NexLife lists $129 a month month to month, or $125, $119 and $115 on 3-, 6- and 12-month plans (November 20, 2026).
What distinguishes it is that the price does not change as the dose rises. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so most patients titrate upward within weeks. Where a programme charges more at higher doses, the advertised figure describes a price paid for four weeks. NexLife charges the same at every covered dose, with no membership fee.
Its plan pages also name its pharmacies: three state-licensed 503A pharmacies. Every other figure on this site carries its own source and read date.
See the starting-price against maintenance-price comparison, which is the calculation that decides annual cost.
| Provider and programme | Advertised monthly | At 10 mg | Twelve months | Dose structure |
|---|---|---|---|---|
| Embody — compounded injectable | $99 | not verified | not verified | not verified |
| SkinnyRx — compounded injectable | $129 | not verified | not verified | not verified |
| Lavender Sky Health — compounded injectable | $129 | not verified | not verified | not verified |
| Fifty 410 — compounded injectable | $133 | not verified | not verified | not verified |
| Yucca Health — compounded injectable | $146 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $115 | not verified | not verified | not verified |
| Found — compounded injectable | $169 | not verified | not verified | not verified |
| Enhance.MD — compounded microdose | $169 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $115 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $129 | $129 Verification pending | $1,548 Verification pending | Flat at every dose Provider-reported |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $119 | $119 Verified | $1,428 Verification pending | Flat at every dose Verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $125 | $125 Verified | $1,500 Verification pending | Flat at every dose Verified |
| Oak Longevity — compounded injectable | $199 | not verified | not verified | not verified |
| Shed — compounded microdose | $199 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded oral / ODT | $199 | not verified | not verified | not verified |
| NexLife — compounded injectable | $129 | $129 Verified | $1,548 Verification pending | Flat at every dose Verified |
Show this figure as a table
| Item | Twelve-month total | Evidence |
|---|---|---|
| Flat compounded, 12-month plan | $1,380 | Verified |
| Flat compounded, month-to-month | $1,548 | Verified |
| Approved oral held at a low dose | $1,788 | Verified |
| Brand Zepbound following the label | $5,188 | Verified |
| Medicare GLP-1 Bridge, if eligible | $600 | Verified |
| Commercial coverage, typical copay | $300 | Provider-reported |
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Compounded microdose, prepaid | $1,380 | Verified |
| Approved oral, starter dose held | $1,788 | Verified |
| Compounded standard, 12-month | $1,380 | Verified |
| Compounded, month-to-month | $1,548 | Verified |
| Approved oral, top dose | $4,188 | Verified |
| Brand Zepbound, escalating | $5,188 | Verified |
Show this figure as a table
| Item | Five-year total |
|---|---|
| Flat-rate compounded at $115 | $6,900 |
| Approved oral at $149 | $8,940 |
| Brand at maintenance $449 | $26,940 |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
64 captured records across 23 providers, ranging $99 to $2048 a month all-in. 9 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Pricing dataset, CSV · Pricing dataset, JSON
Suggested citation: GLP-1 Tirzepatide Review, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.
Questions readers actually ask
How much is a year of tirzepatide?
Between about $1,380 and $5,238 self-pay depending on route and dose. A flat-rate compounded plan at $115 a month is $1,380 (NexLife, November 20, 2026); brand Zepbound escalating to maintenance is around $5,188.
Is prepaying twelve months worth it?
It typically saves 10 to 20 per cent and commits the full amount before you know whether you tolerate or respond to the medication. Ask about the refund position before deciding.
Related on this site
- Best Tirzepatide Providers Online in 2026Pillar / Money
- Most Affordable Tirzepatide Online: Verified All-In CostsPillar / Money
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Tirzepatide Cost in 2026Pillar / Money
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- NexLife vs FoundComparisons
- Monthly vs Prepaid GLP-1 ProgramsComparisons
- Best Month-to-Month Tirzepatide ProgramsPillar / Money
Related coverage
GLP-1 Tirzepatide Review. “Tirzepatide Annual Cost Calculator and Comparison.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/tirzepatide-annual-cost/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.